SG11202003800YA - Zika vaccines and immunogenic compositions, and methods of using the same - Google Patents

Zika vaccines and immunogenic compositions, and methods of using the same

Info

Publication number
SG11202003800YA
SG11202003800YA SG11202003800YA SG11202003800YA SG11202003800YA SG 11202003800Y A SG11202003800Y A SG 11202003800YA SG 11202003800Y A SG11202003800Y A SG 11202003800YA SG 11202003800Y A SG11202003800Y A SG 11202003800YA SG 11202003800Y A SG11202003800Y A SG 11202003800YA
Authority
SG
Singapore
Prior art keywords
methods
same
immunogenic compositions
zika vaccines
zika
Prior art date
Application number
SG11202003800YA
Other languages
English (en)
Inventor
Jill A Livengood
Holli Giebler
Whitney Baldwin
Hansi Dean
Claire Y H Kinney
Original Assignee
Takeda Vaccines Inc
The United States Of America As Represented By The Secretary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc, The United States Of America As Represented By The Secretary filed Critical Takeda Vaccines Inc
Publication of SG11202003800YA publication Critical patent/SG11202003800YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
SG11202003800YA 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same SG11202003800YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581500P 2017-11-03 2017-11-03
US201762592995P 2017-11-30 2017-11-30
PCT/US2018/059219 WO2019090228A2 (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same

Publications (1)

Publication Number Publication Date
SG11202003800YA true SG11202003800YA (en) 2020-05-28

Family

ID=64427224

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11202003800YA SG11202003800YA (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same
SG11202003949TA SG11202003949TA (en) 2017-11-03 2018-11-05 Method for inactivating zika virus and for determining the completeness of inactivation
SG11202003796XA SG11202003796XA (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11202003949TA SG11202003949TA (en) 2017-11-03 2018-11-05 Method for inactivating zika virus and for determining the completeness of inactivation
SG11202003796XA SG11202003796XA (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same

Country Status (12)

Country Link
US (5) US11648304B2 (ru)
EP (3) EP3703741A1 (ru)
JP (4) JP7443232B2 (ru)
KR (3) KR20200117981A (ru)
CN (3) CN111511395A (ru)
AU (6) AU2018359558C1 (ru)
BR (3) BR112020008665A2 (ru)
CA (3) CA3081581A1 (ru)
MX (3) MX2020004542A (ru)
MY (2) MY193736A (ru)
SG (3) SG11202003800YA (ru)
WO (3) WO2019090238A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3703741A1 (en) * 2017-11-03 2020-09-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
BR112020009960A2 (pt) * 2017-11-30 2020-11-10 Takeda Vaccines, Inc. método para a inativação de vírus zika e métodos relacionados
AU2020269164B2 (en) * 2019-05-08 2024-04-04 Takeda Vaccines, Inc. Inactivated virus compositions and Zika vaccine formulations
EP4153222A1 (en) 2020-05-20 2023-03-29 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
US20240133887A1 (en) 2020-10-08 2024-04-25 Takeda Vaccines, Inc. Methods for determining complement-fixing antibodies
CN112980805B (zh) * 2021-02-25 2022-11-08 中国科学院广州生物医药与健康研究院 一种重组寨卡病毒减毒株及其制备方法和应用
CN112941201B (zh) * 2021-03-01 2022-03-08 武汉珈创生物技术股份有限公司 一种用于多细胞种属鉴别和交叉污染检测的混合引物及其使用方法
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
KR102619184B1 (ko) * 2022-12-27 2023-12-29 주식회사 그린백스 에피갈로카테킨-3-갈레이트에 의해 불활화된 지카바이러스를 유효성분으로 포함하는 백신 조성물

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
ES2068989T3 (es) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
EP1175912A1 (en) 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
ES2195151T3 (es) 1996-06-18 2003-12-01 Alza Corp Dispositivo de mejora de aporte o de muestreo de agentes transdermicos.
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
CN1133472C (zh) 1996-12-20 2004-01-07 阿尔萨公司 增加经皮样剂流量的装置
AT405939B (de) * 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
DK1604685T3 (da) 1997-08-28 2012-06-18 Cj Cheiljedang Corp Et svækket japansk encephalitisvirus
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
EP1021548A1 (en) 1997-10-07 2000-07-26 University Of Maryland Biotechnology Institute Method for introducing and expressing rna in animal cells
AU756828B2 (en) 1997-12-02 2003-01-23 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
AU773204C (en) 1998-08-10 2005-05-19 Antigenics Llc Compositions of CPG and saponin adjuvants and methods thereof
CZ20011538A3 (cs) 1998-12-02 2001-11-14 University Of Maryland, Baltimore Nezávisle fungující expresní kazeta, amplifikovatelný plazmidový replikon, bakteriální buňka, vakcinační vektor, podmíněně nestabilní plazmid, způsob vyvolání imunitní odpovědi, DNA a expresní plazmid
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
HUP0303843A3 (en) 2000-11-22 2010-01-28 Univ Maryland Use of clya hemolysin for excretion of proteins
GB0326439D0 (en) 2003-11-13 2003-12-17 Imp College Innovations Ltd Methods
MX2007002372A (es) 2004-08-27 2007-05-08 Panacea Biotec Ltd Vacuna para la poliomielitis inactivada derivada de la cepa sabin del virus de la polio.
PL2179744T3 (pl) 2004-09-09 2011-09-30 Novartis Ag Zmniejszanie potencjału zagrożeń działaniami jatrogennymi związanymi ze szczepionkami przeciwko grypie
EP1724338A1 (en) 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
US8865184B2 (en) 2006-09-01 2014-10-21 Bharat Biotech International Limited Vaccine for chikungunya virus infection
CN103200961B (zh) 2009-03-27 2017-10-27 中央研究院 抗病毒免疫的方法和组合物
CN101954076A (zh) 2009-04-27 2011-01-26 免疫制剂美国公司 自身免疫性肝炎的免疫疗法和预防
PE20140646A1 (es) 2011-05-26 2014-05-29 Glaxosmithkline Biolog Sa Vacuna de virus de dengue inactivado
KR101792684B1 (ko) 2011-06-17 2017-11-02 브하라트 바이오테크 인터내셔날 리미티드 불활성화된 치쿤구니야 바이러스 균주를 포함하는 백신 조성물
EP3269386B1 (en) 2011-12-06 2022-09-14 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
RU2706693C2 (ru) 2013-09-14 2019-11-20 Бхарат Байотек Интернэшнл Лимитед Вирусная вакцина и способы ее производства
KR20170066433A (ko) 2014-09-17 2017-06-14 더 유니버시티 오브 아이오와 리서치 파운데이션 면역조절제 및 백신 성분으로서 바이러스 rna 분절
KR102219638B1 (ko) 2014-10-07 2021-02-23 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 엔테로바이러스 불활화 및 보강제 흡착 방법과 이로부터 수득되는 저용량 백신 조성물
MA40920A (fr) 2014-11-07 2017-09-12 Takeda Vaccines Inc Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
WO2016145149A1 (en) 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
BR112017027770A2 (pt) 2015-06-22 2018-09-11 Harvard College composições e métodos para modular infecção viral
EP3322441A4 (en) * 2015-07-16 2018-12-19 Bharat Biotech International Limited Vaccine compositions
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
EP3355899A4 (en) 2015-09-30 2019-04-03 Ramot at Tel-Aviv University Ltd. In place of EVOLUTIONARY PRESERVED RNA STRUCTURE MUTATED APPROVED VIRUS
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
PL3393510T3 (pl) * 2015-12-23 2023-06-26 Valneva Austria Gmbh Szczepionka przeciwko wirusowi zika
US11434259B2 (en) 2016-01-25 2022-09-06 Iogenetics, Llc Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
MX2018009917A (es) 2016-02-17 2019-08-14 Curevac Ag Vacuna contra el virus del zika.
MX2018010291A (es) 2016-02-25 2019-06-06 Univ Pennsylvania Vacunas novedosas contra el virus de zika.
US20170354729A1 (en) 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
CN105749268B (zh) * 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
US20170298119A1 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
WO2017192856A1 (en) 2016-05-04 2017-11-09 University Of Miami Zika virus vector for treating zika virus infection
ES2929274T3 (es) 2016-05-10 2022-11-28 Najit Tech Inc Inactivación de patógenos y producción de vacunas inactivadas altamente inmunógenas utilizando un proceso de oxidación dual
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
BE1024796B9 (fr) 2016-06-02 2019-01-08 Glaxosmithkline Biologicals Sa Constructions antigeniques du virus zika
US10611801B2 (en) 2016-06-09 2020-04-07 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for preventing and treating Zika virus infection
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
BR112018075513A2 (pt) 2016-06-13 2019-10-01 Us Health ácidos nucleicos que codificam as partículas seme-lhantes ao vírus da zika e seu uso nas vacinas e no ensaio de diagnóstico do vírus da zika
EP3481848B1 (en) 2016-07-08 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Genomic sequences encoding for an attenuated mutant zika virus
WO2018009603A1 (en) 2016-07-08 2018-01-11 The United State of America, as represented by the Secretary, Department of Health and Human Service Chimeric west nile/zika viruses and methods of use
WO2018022786A1 (en) 2016-07-26 2018-02-01 Washington University Antibodies to zika virus and methods of use thereof
GB201613191D0 (en) 2016-07-29 2016-09-14 Univ Oxford Innovation Ltd Zika virus vaccine
WO2018091540A1 (en) 2016-11-17 2018-05-24 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
EP3558353A2 (en) 2016-12-23 2019-10-30 Expres2ion Biotechnologies ApS New flavivirus vaccine
CN108503696B (zh) 2017-02-27 2023-05-12 中国科学院上海巴斯德研究所 一种酵母细胞表达的寨卡病毒亚单位疫苗
CN108503697B (zh) 2017-02-27 2023-03-31 中国科学院上海巴斯德研究所 一种果蝇细胞表达的寨卡病毒亚单位疫苗
WO2018165373A1 (en) 2017-03-08 2018-09-13 University Of Georgia Research Foundation, Inc. Methods and compositions related to increased viral production
WO2018187799A1 (en) 2017-04-07 2018-10-11 The Rockefeller University Compositions and methods related to human neutralizing antibodies to zika and dengue 1 virus
WO2018237039A1 (en) 2017-06-20 2018-12-27 Texas Tech University System ZIKA VIRAL PSEUDO PARTICLE VACCINE (VLP) VACCINE AND MICRONEUTRALIZATION ASSAY
EP3417943B1 (de) 2017-06-21 2020-02-12 Eppendorf AG Zentrifugenrotor mit abdichtung
CN107188935B (zh) * 2017-07-20 2018-10-02 北京健乃喜生物技术有限公司 一种寨卡病毒ns1抗原突变体及其应用
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN107537029B (zh) 2017-09-14 2021-03-19 北京科兴生物制品有限公司 一种寨卡病毒与黄热病毒联合灭活疫苗
GB201716254D0 (en) 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
EP3703741A1 (en) * 2017-11-03 2020-09-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
BR102017024030A2 (pt) 2017-11-08 2019-06-04 Universidade Federal De São João Del Rei Proteína recombinante imunogênica com antígenos de zika virus para vacina e seus usos
WO2019104157A1 (en) 2017-11-21 2019-05-31 The University Of Vermont And State Agricultural College Highly specific zika neutralizing human antibodies
BR112020009960A2 (pt) 2017-11-30 2020-11-10 Takeda Vaccines, Inc. método para a inativação de vírus zika e métodos relacionados
CN108187036A (zh) 2017-12-08 2018-06-22 北京科兴中维生物技术有限公司 一种寨卡病毒与乙脑病毒联合灭活疫苗
CN108210921A (zh) 2017-12-29 2018-06-29 广州恩宝生物医药科技有限公司 一种寨卡病毒疫苗及其制备方法
US20210087617A1 (en) 2018-02-22 2021-03-25 Nano4 Global, Lda Method for detecting flaviviridae
AU2018411586A1 (en) 2018-03-08 2020-09-03 Codagenix Inc. Attenuated flaviviruses
AU2019244435A1 (en) 2018-03-29 2020-10-15 Emergex Vaccines Holding Limited Vaccine compositions
KR102075581B1 (ko) 2018-04-27 2020-02-10 가톨릭대학교 산학협력단 바이러스성 발현 조절 서열이 삽입된 핵산 분자를 포함하는 면역보강제 및 이를 포함하는 약학 조성물
KR102253190B1 (ko) 2018-07-18 2021-05-18 (주)진매트릭스 지카 바이러스 변이주와 이를 포함한 지카 백신 조성물
EP3851120A4 (en) 2018-09-11 2022-04-27 Shanghai Public Health Clinical Center IMMUNOGEN FOR BROAD-SPECTRUM INFLUENZA VACCINE, AND APPLICATION THEREOF
US20210308250A1 (en) 2018-10-26 2021-10-07 New York Blood Center, Inc. Zika virus immunogenic compositions
EP3883961A1 (en) 2018-11-20 2021-09-29 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
AU2020269164B2 (en) 2019-05-08 2024-04-04 Takeda Vaccines, Inc. Inactivated virus compositions and Zika vaccine formulations
US20230272405A1 (en) 2020-06-22 2023-08-31 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor

Also Published As

Publication number Publication date
EP3703739A2 (en) 2020-09-09
AU2018359556B2 (en) 2021-12-02
WO2019090233A2 (en) 2019-05-09
AU2022201109B9 (en) 2022-05-12
AU2022201109A1 (en) 2022-03-10
JP2021502075A (ja) 2021-01-28
KR20200083571A (ko) 2020-07-08
SG11202003949TA (en) 2020-05-28
MX2020004367A (es) 2020-10-19
US11648304B2 (en) 2023-05-16
AU2018359660B2 (en) 2022-02-24
WO2019090238A1 (en) 2019-05-09
BR112020008652A2 (pt) 2020-11-10
WO2019090228A2 (en) 2019-05-09
AU2022201109B2 (en) 2022-04-28
JP7295124B2 (ja) 2023-06-20
US11478541B2 (en) 2022-10-25
AU2018359558B2 (en) 2021-12-02
CA3081578A1 (en) 2019-05-09
AU2018359556A1 (en) 2020-05-28
SG11202003796XA (en) 2020-05-28
AU2022203422B2 (en) 2023-10-05
JP2021502350A (ja) 2021-01-28
MX2020004543A (es) 2020-09-18
US20210177958A1 (en) 2021-06-17
AU2018359558A1 (en) 2020-05-28
AU2022203422A1 (en) 2022-06-09
AU2018359660A1 (en) 2020-05-28
EP3703740A2 (en) 2020-09-09
BR112020008665A2 (pt) 2020-11-10
WO2019090228A3 (en) 2019-06-20
KR20200117981A (ko) 2020-10-14
MY193736A (en) 2022-10-27
MY194449A (en) 2022-11-30
CA3081581A1 (en) 2019-05-09
WO2019090233A3 (en) 2019-06-13
MX2020004542A (es) 2020-09-18
JP2021505648A (ja) 2021-02-18
AU2022209239A1 (en) 2022-08-18
CN111511395A (zh) 2020-08-07
US20200360505A1 (en) 2020-11-19
AU2022209239B2 (en) 2023-10-05
BR112020008693A2 (pt) 2020-10-13
CN111526885A (zh) 2020-08-11
US20210177959A1 (en) 2021-06-17
EP3703741A1 (en) 2020-09-09
US11964008B2 (en) 2024-04-23
CA3081586A1 (en) 2019-05-09
AU2018359558C1 (en) 2022-09-22
US11730802B2 (en) 2023-08-22
US20230414743A1 (en) 2023-12-28
KR20200085302A (ko) 2020-07-14
JP2023175761A (ja) 2023-12-12
JP7443232B2 (ja) 2024-03-05
CN111615397A (zh) 2020-09-01
US20230145065A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
SG11202003796XA (en) Zika vaccines and immunogenic compositions, and methods of using the same
HUS2200035I1 (hu) Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik
HK1250136A1 (zh) 具有改善的穩定性和免疫原性之疫苗組合物
SG11202004863QA (en) Zika vaccines and immunogenic compositions, and methods of using the same
IL268168A (en) Immunogenic preparations for use as a vaccine against pneumococcus
ZA202000889B (en) An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
IL269590A (en) Methods and compositions for reducing immunogenicity
IL251120A0 (en) Immunogenic/therapeutic glycoside preparations and their uses
SG11201803581VA (en) Chimeric RSV, Immunogenic Compositions, and Methods of Use
GB201721582D0 (en) S aureus antigens and immunogenic compositions
EP3307311A4 (en) MULTIVALENT ENTEROVIRUS VACCINE COMPOSITIONS AND USES THEREOF
IL271603A (en) Immunogenic preparations
IL258700A (en) An excipient and a vaccine that includes it
GB2570806B (en) Immunogenic agent and associated compositions, uses and methods
GB201911959D0 (en) Immunogenic compositions and uses therefor
SG11202004167XA (en) Immunogenic compositions and uses therefor
AU2017904540A0 (en) Immunogenic compositions and uses therefor
AU2014902031A0 (en) Immunogenic vaccines and uses thereof